Featured Research

from universities, journals, and other organizations

Melbourne Dementia Discovery Chosen For Synchrotron Testing

Date:
June 22, 2007
Source:
Howard Florey Institute
Summary:
A protein involved in memory that has the potential to be developed into a treatment for dementia and other forms of memory loss will be one of the first proteins to be visualised on Australia's new synchrotron, before it opens for general use later this year.

Left to right: Dr Peta Burns and Dr Siew Yeen Chai are developing drugs to improve learning and memory.
Credit: Image courtesy of Siew Chai and Howard Florey Institute

A protein involved in memory that has the potential to be developed into a treatment for dementia and other forms of memory loss will be one of the first proteins to be visualised on Australia's new synchrotron, before it opens for general use later this year.

The Australian Synchrotron experiment will play a pivotal role in helping scientists from Melbourne's Howard Florey Institute and St Vincent's Institute to analyse how recently identified compounds, which improve memory in rats, interact with the protein, called insulin-regulated aminopeptidase (IRAP).

Data from the experiment, which began on 6 June, will help the scientists refine the structure of these compounds so that they bind better to the IRAP protein, which is the next step in developing a drug that enhances and restores memory.

Dr Siew Yeen Chai from the Howard Florey Institute said these IRAP-binding compounds had already proven to be promising candidates for a drug to treat dementia and other forms of memory loss, including amnesia.

"Within five minutes of giving experimental rats a single injection of these compounds, the animals display a dramatically improved ability to run mazes, which is a standard memory test," Dr Chai said.

Prof Michael Parker, an international leader in structural biology and Australian Research Council Federation Fellow at St Vincent's Institute, was invited to submit projects for the Australian Synchrotron and chose his collaboration project with Dr Chai as one of the first proteins to be analysed at the new facility. For the past few months, Prof Parker's team have been preparing a crystal form of IRAP bound to one of the promising compounds so it can be tested at the Australian Synchrotron.

Prof Parker said the synchrotron produces an extremely high intensity light beam that is used to see objects that are too small to be seen with a normal microscope.

"The beam will hit the IRAP crystal and will scatter to reveal the 3-D atomic shape of IRAP and show us how the compounds bind to and interact with IRAP," Prof Parker said.

"Once we know how these compounds interact with IRAP, we can refine their structures so they bind more tightly, thus reducing the possibility of side-effects when the compounds are developed into a treatment for humans," he said.

Around six years ago, Dr Chai and her Florey colleague, Dr Anthony Albiston, discovered IRAP, a specific protein in the brain that certain compounds act on to enhance learning and memory, as well as reverse memory deficits.

For the past four years, the Florey scientists, in collaboration with Prof Parker's lab, have been searching for synthetic compounds that bind specifically to IRAP using a computer model of the protein.

Now the scientists are excited that the Australian Synchrotron experiment will speed up their drug-development research.

"The Australian Synchrotron is helping us to rapidly accelerate this research as we are able to collect, in hours, data on IRAP's structure that would usually take months," Prof Parker said.

"Access to the Australian Synchrotron also allows us to use smaller amounts of the scarce material being tested and provides an accurate protein structure," he said.

This drug development project is being funded by a National Health and Medical Research Council drug development grant, Neurosciences Victoria, and the Institute for the Study of Aging in the US, but the Florey is now looking for a commercial partner to invest in this research.


Story Source:

The above story is based on materials provided by Howard Florey Institute. Note: Materials may be edited for content and length.


Cite This Page:

Howard Florey Institute. "Melbourne Dementia Discovery Chosen For Synchrotron Testing." ScienceDaily. ScienceDaily, 22 June 2007. <www.sciencedaily.com/releases/2007/06/070614093455.htm>.
Howard Florey Institute. (2007, June 22). Melbourne Dementia Discovery Chosen For Synchrotron Testing. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2007/06/070614093455.htm
Howard Florey Institute. "Melbourne Dementia Discovery Chosen For Synchrotron Testing." ScienceDaily. www.sciencedaily.com/releases/2007/06/070614093455.htm (accessed September 18, 2014).

Share This



More Mind & Brain News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Corporal Punishment on Decline, Debate Renews

Corporal Punishment on Decline, Debate Renews

AP (Sep. 16, 2014) Corporal punishment in the United States is on the decline, but there is renewed debate over its use after Minnesota Vikings running back Adrian Peterson was charged with child abuse. (Sept. 16) Video provided by AP
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Shocker: Journalists Are Utterly Addicted To Coffee

Shocker: Journalists Are Utterly Addicted To Coffee

Newsy (Sep. 13, 2014) A U.K. survey found that journalists consumed the most amount of coffee, but that's only the tip of the coffee-related statistics iceberg. Video provided by Newsy
Powered by NewsLook.com
'Magic Mushrooms' Could Help Smokers Quit

'Magic Mushrooms' Could Help Smokers Quit

Newsy (Sep. 11, 2014) In a small study, researchers found that the majority of long-time smokers quit after taking psilocybin pills and undergoing therapy sessions. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins